Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology

Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors. SEATTLE and PESSAC, France / June 10th, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf,...